Tim McCarthy, chairman of ImmuPharma PLC (LON:IMM), says lupus treatment Lupuzor will be entered into managed access programme to allow sufferers whose doctors recommend it.
Immupharma will get ‘real-world’ data from the MAP with up to 500 patients to receive the drug free of charge for two years.
That is more than twice the number of patients studied in all clinical trials for Lupuzor to date.
Chairman Tim McCarthy talks to DirectorsTalk about the further analysis of the results from its pivotal Phase III trial of Lupuzor and final results.
Tim McCarthy, chairman of ImmuPharma PLC (LON:IMM) tells Proactive that there is a strong indication that in certain populations of lupus patients, its Lupuzor drug works very effectively. McCarthy was talking after a deeper dive into the data generated…
ImmuPharma PLC (LON:IMM) CEO Dimitri Dimitriou and chairman Tim McCarthy discuss with Proactive Investors the top-line results from their phase III trial of the drug Lupuzor.
ImmuPharma PLC (LON:IMM) Chairman Tim McCarthy caught up with DirectorsTalk for an exclusive interview to discuss the topline results of their Lupuzor Phase III trial. For full transcript click here
Tim McCarthy, Chairman of Immupharma discusses the topline results of the Lupuzor Pivotal Phase III Trial.
A great start to 2018 with pivotal Phase III data for Lupuzor™ only weeks away.
Tim McCarthy, Chairman of Immupharma discusses the completion of Lupuzor™ pivotal phase III study and initiation of follow up study.
ImmuPharma PLC (LON:IMM) is the topic of conversation when Northland Capital Partners Head of Research Vadim Alexandre caught up with DirectorsTalk for an exclusive interview.
Tim McCarthy talks to DirectorsTalk about its Lupuzor market update. Tim explains the main points to the update, the importance of reaching a milestone where all patients have been dosed for over three months, the importance of announcements to shareholders and confidence of providing top line results in Q1 2018.
Tim McCarthy, chairman of ImmuPharma PLC (LON:IMM) tells Proactive they’re on schedule to publish first results from their phase III trial of lupus drug Lupuzor early next year with all 200 patients now having had at least three months worth of treatment.
Tim McCarthy, Chairman of ImmuPharma gives an update, on its lead compound, Lupuzor™ in its pivotal Phase III study on this audio podcast
Tim McCarthy, Chairman of ImmuPharma PLC , presents at the Biotech Capital Conference: 2017
Tim McCarthy, chairman of ImmuPharma PLC (LON:IMM) spoke to Proactive Investors to give an update on the company’s progress with its phase-III clinical trial of Lupuzor™, a treatment for Lupus – a life threatening auto-immune disease.